desvenlafaxine-succinate and Attention-Deficit-Disorder-with-Hyperactivity

desvenlafaxine-succinate has been researched along with Attention-Deficit-Disorder-with-Hyperactivity* in 1 studies

Trials

1 trial(s) available for desvenlafaxine-succinate and Attention-Deficit-Disorder-with-Hyperactivity

Article	Year
Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:4 The objectives of this pilot study were to explore the changes in symptom severity, tolerability, and the pharmacodynamics of venlafaxine treatment in youths with attention-deficit/hyperactivity disorder (ADHD).. This was a 2-week, open-label, outpatient trial of venlafaxine in children and adolescents, ages 5-17 years, with ADHD. Three dosing strata, 0.5, 1.0, and 2.0 mg/kg per day, were examined. ADHD symptom severity and improvement assessments included the ADHD Rating Scale (ARS-IV) and the Clinical Global Impressions Scale (CGI). During this study, venlafaxine, O-desmethylvenlafaxine (ODV), norepinephrine, and serotonin concentrations were obtained.. Thirty-eight participants (33 males) were treated in this trial. Overall, parent-completed and teacher-completed ARS-IV total scores showed a statistically significant positive change at the end of the study when compared to baseline (p < 0.05). Significant increases in plasma venlafaxine concentrations were observed at day 15 when compared to day 8 (p = 0.04). In addition, plasma norepinephrine and serotonin concentrations were found to be significantly decreased from baseline at end of study (p < 0.05). Four patients ended participation in the study prematurely: lost to follow up (n = 2), withdrawal of consent (n = 1), and worsening of ADHD symptoms after 8 days of treatment (n = 1). There were no discontinuations due to other adverse events.. Venlafaxine appeared to offer some benefit and appears to be relatively safe for the short-term treatment of ADHD in this open-label trial. The pharmacodynamics of venlafaxine in youths are consistent with serotonergic and neuradrenergic modulation. Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Faculty; Female; Humans; Male; Norepinephrine; Parents; Pilot Projects; Psychiatric Status Rating Scales; Psychometrics; Selective Serotonin Reuptake Inhibitors; Serotonin; Severity of Illness Index; Venlafaxine Hydrochloride	2007

Article

Year

Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder.

Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:4

The objectives of this pilot study were to explore the changes in symptom severity, tolerability, and the pharmacodynamics of venlafaxine treatment in youths with attention-deficit/hyperactivity disorder (ADHD).. This was a 2-week, open-label, outpatient trial of venlafaxine in children and adolescents, ages 5-17 years, with ADHD. Three dosing strata, 0.5, 1.0, and 2.0 mg/kg per day, were examined. ADHD symptom severity and improvement assessments included the ADHD Rating Scale (ARS-IV) and the Clinical Global Impressions Scale (CGI). During this study, venlafaxine, O-desmethylvenlafaxine (ODV), norepinephrine, and serotonin concentrations were obtained.. Thirty-eight participants (33 males) were treated in this trial. Overall, parent-completed and teacher-completed ARS-IV total scores showed a statistically significant positive change at the end of the study when compared to baseline (p < 0.05). Significant increases in plasma venlafaxine concentrations were observed at day 15 when compared to day 8 (p = 0.04). In addition, plasma norepinephrine and serotonin concentrations were found to be significantly decreased from baseline at end of study (p < 0.05). Four patients ended participation in the study prematurely: lost to follow up (n = 2), withdrawal of consent (n = 1), and worsening of ADHD symptoms after 8 days of treatment (n = 1). There were no discontinuations due to other adverse events.. Venlafaxine appeared to offer some benefit and appears to be relatively safe for the short-term treatment of ADHD in this open-label trial. The pharmacodynamics of venlafaxine in youths are consistent with serotonergic and neuradrenergic modulation.

Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cyclohexanols; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Faculty; Female; Humans; Male; Norepinephrine; Parents; Pilot Projects; Psychiatric Status Rating Scales; Psychometrics; Selective Serotonin Reuptake Inhibitors; Serotonin; Severity of Illness Index; Venlafaxine Hydrochloride

2007